Novel heterocyclic compounds of the formula (I), in which R
1
, D, W, T and T′ have the meanings indicated in Claim
1
, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and conditions, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type.
公式(I)的新型
杂环化合物,其中R1、D、W、T和T′具有权利要求书1中所示的含义,是SGK
抑制剂,可用于治疗SGK引起的疾病和病症,例如糖尿病、肥胖症、代谢综合征(血脂异常)、全身和肺动脉高压、心血管疾病和肾脏疾病,通常用于任何类型的纤维化和炎症过程。